Three-dimensional microenvironment confers enhanced sensitivity to doxorubicin by reducing p53-dependent induction of autophagy

Oncogene

Volumn 34, Issue 42, 2015, Pages 5329-5340

  Gomes, L R ^a   Vessoni, A T ^a   Menck, C F M ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOPHAGY PROTEIN 5; CHLOROQUINE; DOXORUBICIN; DRAM 1 PROTEIN; LAMININ; PROTEIN; PROTEIN P53; RAPAMYCIN; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIBIOTIC; DRAM1 PROTEIN, HUMAN; MEMBRANE PROTEIN; TP53 PROTEIN, HUMAN;

ARTICLE; AUTOPHAGY; BREAST CANCER; BREAST CANCER CELL LINE; CANCER RESISTANCE; CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL DEATH; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DRUG SENSITIVITY; EXTRACELLULAR MATRIX; GENE SILENCING; HUMAN; HUMAN CELL; MCF 7 CELL LINE; MONOLAYER CULTURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; DRUG EFFECTS; FEMALE; PHYSIOLOGY;

ANTIBIOTICS, ANTINEOPLASTIC; AUTOPHAGY; CELLULAR MICROENVIRONMENT; DNA DAMAGE; DOXORUBICIN; EXTRACELLULAR MATRIX; FEMALE; HUMANS; MCF-7 CELLS; MEMBRANE PROTEINS; SIROLIMUS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84945475729     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.461     Document Type: Article

References (56)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics2012. CA Cancer J Clin 2012; 62: 10-29.
2. Khasraw M, Bell R, Dang C. Epirubicin: is it like doxorubicin in breast cancer? A clinical review. Breast 2012; 21: 142-149.
3. DeSantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin 2014; 64: 52-62.
4. Ahn JH, Lee M. Suppression of autophagy sensitizes multidrug resistant cells towards Src tyrosine kinase specific inhibitor PP2. Cancer Lett 2011; 310: 188-197.
5. Liang B, Kong D, Liu Y, Liang N, He M, Ma S et al. Autophagy inhibition plays the synergetic killing roles with radiation in the multi-drug resistant SKVCR ovarian cancer cells. Radiat Oncol 2012; 7: 213.
6. Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008; 132: 27-42.
7. Singh R, Cuervo AM. Autophagy in the cellular energetic balance. Cell Metab 2011; 13: 495-504.
8. Chen Y, Azad MB, Gibson SB. Superoxide is the major reactive oxygen species regulating autophagy. Cell Death Differ 2009; 16: 1040-1052.
9. Crighton D, Wilkinson S, O'Prey J, Syed N, Smith P, Harrison PR et al. DRAM, a p53-induced modulator of autophagy, is critical for apoptosis. Cell 2006; 126: 121-134.
10. Manov I, Pollak Y, Broneshter R, Iancu TC. Inhibition of doxorubicin-induced autophagy in hepatocellular carcinoma Hep3B cells by sorafenib-the role of extracellular signal-regulated kinase counteraction. FEBS J 2011; 278: 3494-3507.
11. Mathew R, White E. Autophagy, stress, and cancer metabolism: what doesn't kill you makes you stronger. Cold Spring Harb Symp Quant Biol 2011; 76: 389-396.
12. Kimmelman AC. The dynamic nature of autophagy in cancer. Genes Dev 2011; 25: 1999-2010.
13. Qu X, Zou Z, Sun Q, Luby-Phelps K, Cheng P, Hogan RN et al. Autophagy genedependent clearance of apoptotic cells during embryonic development. Cell 2007; 128: 931-946.
14. Weaver VM, Bissell MJ. Functional culture models to study mechanisms governing apoptosis in normal and malignant mammary epithelial cells. J Mammary Gland Biol Neoplasia 1999; 4: 193-201.
15. Kenny PA, Lee GY, Myers CA, Neve RM, Semeiks JR, Spellman PT et al. The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol Oncol 2007; 1: 84-96.
16. Lee GY, Kenny PA, Lee EH, Bissell MJ. Three-dimensional culture models of normal and malignant breast epithelial cells. Nat Methods 2007; 4: 359-365.
17. Valbuena A, Castro-Obregon S, Lazo PA. Downregulation of VRK1 by p53 in response to DNA damage is mediated by the autophagic pathway. PLoS One 2011; 6: e17320.
18. Mohan P, Rapoport N. Doxorubicin as a molecular nanotheranostic agent: effect of doxorubicin encapsulation in micelles or nanoemulsions on the ultrasoundmediated intracellular delivery and nuclear trafficking. Mol Pharm 2010; 7: 1959-1973.
19. Li Q, Chow AB, Mattingly RR. Three-dimensional overlay culture models of human breast cancer reveal a critical sensitivity to mitogen-activated protein kinase kinase inhibitors. J Pharmacol Exp Ther 2010; 332: 821-828.
20. Woodley-Cook J, Shin LY, Swystun L, Caruso S, Beaudin S, Liaw PC. Effects of the chemotherapeutic agent doxorubicin on the protein C anticoagulant pathway. Mol Cancer Ther 2006; 5: 3303-3311.
21. Swenson CE, Bolcsak LE, Batist G, Guthrie TH Jr., Tkaczuk KH, Boxenbaum H et al. Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposomeencapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer. Anticancer Drugs 2003; 14: 239-246.
22. Bramwell VH, Morris D, Ernst DS, Hings I, Blackstein M, Venner PM et al. Safety and efficacy of the multidrug-resistance inhibitor biricodar (VX-710) with concurrent doxorubicin in patients with anthracycline-resistant advanced soft tissue sarcoma. Clin Cancer Res 2002; 8: 383-393.
23. Sun WL, Chen J, Wang YP, Zheng H. Autophagy protects breast cancer cells from epirubicin-induced apoptosis and facilitates epirubicin-resistance development. Autophagy 2011; 7: 1035-1044.
24. Mizushima N, Yoshimori T. How to interpret LC3 immunoblotting. Autophagy 2007; 3: 542-545.
25. Cortat B, Garcia CC, Quinet A, Schuch AP, de Lima-Bessa KM, Menck CF. The relative roles of DNA damage induced by UVA irradiation in human cells. Photochem Photobiol Sci 2013; 12: 1483-1495.
26. Moraes MC, de Andrade AQ, Carvalho H, Guecheva T, Agnoletto MH, Henriques JA et al. Both XPA and DNA polymerase eta are necessary for the repair of doxorubicin-induced DNA lesions. Cancer Lett 2012; 314: 108-118.
27. Cheng YJ, Lee CH, Lin YP, Huang JY, Su CC, Chang WT et al. Caspase-3 enhances lung metastasis and cell migration in a proteaseindependent mechanism through the ERK pathway. Int J Cancer 2008; 123: 1278-1285.
28. Pyo JO, Yoo SM, Ahn HH, Nah J, Hong SH, Kam TI et al. Overexpression of Atg5 in mice activates autophagy and extends lifespan. Nat Commun 2013; 4: 2300.
29. Batista LF, Roos WP, Christmann M, Menck CF, Kaina B. Differential sensitivity of malignant glioma cells to methylating and chloroethylating anticancer drugs: p53 determines the switch by regulating xpc, ddb2, and DNA double-strand breaks. Cancer Res 2007; 67: 11886-11895.
30. Beckta JM, Ahmad SF, Yang H, Valerie K. Revisiting p53 for cancer-specific chemoand radiotherapy: Ten years after. Cell Cycle 2014; 13: 710-713.
31. Bertheau P, Lehmann-Che J, Varna M, Dumay A, Poirot B, Porcher R et al. p53 in breast cancer subtypes and new insights into response to chemotherapy. Breast 2013; 22: S27-S29.
32. Li DD, Sun T, Wu XQ, Chen SP, Deng R, Jiang S et al. The inhibition of autophagy sensitises colon cancer cells with wild-type p53 but not mutant p53 to topotecan treatment. PLoS One 2012; 7: e45058.
33. Scherz-Shouval R, Weidberg H, Gonen C, Wilder S, Elazar Z, Oren M. p53-dependent regulation of autophagy protein LC3 supports cancer cell survival under prolonged starvation. Proc Natl Acad Sci USA 2010; 107: 18511-18516.
34. Maycotte P, Gearheart CM, Barnard R, Aryal S, Mulcahy Levy JM, Fosmire SP et al. STAT3-mediated autophagy dependence identifies subtypes of breast cancer where autophagy inhibition can be efficacious. Cancer Res 2014; 74: 2579-2590.
35. Selvakumaran M, Amaravadi RK, Vasilevskaya IA, O'Dwyer PJ. Autophagy inhibition sensitizes colon cancer cells to antiangiogenic and cytotoxic therapy. Clin Cancer Res 2013; 19: 2995-3007.
36. Amaravadi RK, Lippincott-Schwartz J, Yin XM, Weiss WA, Takebe N, Timmer W et al. Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res 2011; 17: 654-666.
37. Bristol ML, Emery SM, Maycotte P, Thorburn A, Chakradeo S, Gewirtz DA. Autophagy inhibition for chemosensitization and radiosensitization in cancer: do the preclinical data support this therapeutic strategy? J Pharmacol Exp Ther 2013; 344: 544-552.
38. Pampaloni F, Reynaud EG, Stelzer EH. The third dimension bridges the gap between cell culture and live tissue. Nat Rev Mol Cell Biol 2007; 8: 839-845.
39. Bissell MJ, Weaver VM, Lelievre SA, Wang F, Petersen OW, Schmeichel KL. Tissue structure, nuclear organization, and gene expression in normal and malignant breast. Cancer Res 1999; 59: 1757-1763s discussion 1763s-1764s.
40. Edick MJ, Tesfay L, Lamb LE, Knudsen BS, Miranti CK. Inhibition of integrin-mediated crosstalk with epidermal growth factor receptor/Erk or Src signaling pathways in autophagic prostate epithelial cells induces caspaseindependent death. Mol Biol Cell 2007; 18: 2481-2490.
41. Tuloup-Minguez V, Greffard A, Codogno P, Botti J. Regulation of autophagy by extracellular matrix glycoproteins in HeLa cells. Autophagy 2011; 7: 27-39.
42. Novaro V, Roskelley CD, Bissell MJ. Collagen-IV and laminin-1 regulate estrogen receptor alpha expression and function in mouse mammary epithelial cells. J Cell Sci 2003; 116: 2975-2986.
43. Debnath J. Detachment-induced autophagy during anoikis and lumen formation in epithelial acini. Autophagy 2008; 4: 351-353.
44. Lock R, Debnath J. Extracellular matrix regulation of autophagy. Curr Opin Cell Biol 2008; 20: 583-588.
45. Fung C, Lock R, Gao S, Salas E, Debnath J. Induction of autophagy during extracellular matrix detachment promotes cell survival. Mol Biol Cell 2008; 19: 797-806.
46. Crighton D, Wilkinson S, Ryan KM. DRAM links autophagy to p53 and programmed cell death. Autophagy 2007; 3: 72-74.
47. Velez JM, Miriyala S, Nithipongvanitch R, Noel T, Plabplueng CD, Oberley T et al. p53 Regulates oxidative stress-mediated retrograde signaling: a novel mechanism for chemotherapy-induced cardiac injury. PLoS One 2011; 6: e18005.
48. Jackson JG, Pant V, Li Q, Chang LL, Quintas-Cardama A, Garza D et al. p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer. Cancer Cell 2012; 21: 793-806.
49. Tasdemir E, Chiara Maiuri M, Morselli E, Criollo A, D'Amelio M, Djavaheri-Mergny M et al. A dual role of p53 in the control of autophagy. Autophagy 2008; 4: 810-814.
50. Green DR, Kroemer G. Cytoplasmic functions of the tumour suppressor p53. Nature 2009; 458: 1127-1130.
51. Bhana S, Lloyd DR. The role of p53 in DNA damage-mediated cytotoxicity overrides its ability to regulate nucleotide excision repair in human fibroblasts. Mutagenesis 2008; 23: 43-50.
52. do Amaral JB, Rezende-Teixeira P, Freitas VM, Machado-Santelli GM. MCF-7 cells as a three-dimensional model for the study of human breast cancer. Tissue Eng Part C Methods 2011; 17: 1097-1107.
53. Quinet A, Vessoni AT, Rocha CR, Gottifredi V, Biard D, Sarasin A et al. Gap-filling and bypass at the replication fork are both active mechanisms for tolerance of low-dose ultraviolet-induced DNA damage in the human genome. DNA Repair (Amst) 2014; 14: 27-38.
54. Ghavami S, Mutawe MM, Sharma P, Yeganeh B, McNeill KD, Klonisch T et al. Mevalonate cascade regulation of airway mesenchymal cell autophagy and apoptosis: a dual role for p53. PLoS One 2011; 6: e16523.
55. Gomes LR, Terra LF, Wailemann RA, Labriola L, Sogayar MC. TGF-beta1 modulates the homeostasis between MMPs and MMP inhibitors through p38 MAPK and ERK1/2 in highly invasive breast cancer cells. BMC Cancer 2012; 12: 26.
56. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C (T) method. Nat Protoc 2008; 3: 1101-1108.